27,482 Shares in Neurogene Inc. $NGNE Bought by Nuveen LLC

Nuveen LLC purchased a new stake in Neurogene Inc. (NASDAQ:NGNE) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 27,482 shares of the company’s stock, valued at approximately $322,000. Nuveen LLC owned 0.19% of Neurogene at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its position in shares of Neurogene by 2,985.1% in the first quarter. GAMMA Investing LLC now owns 4,134 shares of the company’s stock valued at $48,000 after acquiring an additional 4,000 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Neurogene by 34.5% during the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock worth $124,000 after purchasing an additional 1,397 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Neurogene by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 11,231 shares of the company’s stock worth $132,000 after purchasing an additional 941 shares during the period. Bank of New York Mellon Corp grew its holdings in Neurogene by 8.2% during the first quarter. Bank of New York Mellon Corp now owns 24,445 shares of the company’s stock worth $286,000 after purchasing an additional 1,844 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in Neurogene during the fourth quarter worth about $322,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Price Performance

Shares of NGNE opened at $19.95 on Friday. Neurogene Inc. has a one year low of $6.88 and a one year high of $74.49. The company has a market cap of $284.69 million, a P/E ratio of -4.63 and a beta of 1.58. The firm has a 50 day simple moving average of $20.65 and a two-hundred day simple moving average of $17.41.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Monday, August 11th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.10. On average, analysts expect that Neurogene Inc. will post -4.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NGNE. Baird R W cut Neurogene from a “strong-buy” rating to a “hold” rating in a report on Friday, May 16th. BMO Capital Markets restated an “outperform” rating and set a $26.00 price objective (up previously from $22.00) on shares of Neurogene in a report on Thursday, June 12th. Craig Hallum began coverage on Neurogene in a report on Tuesday, June 17th. They set a “buy” rating and a $50.00 price objective for the company. Robert W. Baird cut Neurogene from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $38.00 to $24.00 in a report on Friday, May 16th. Finally, HC Wainwright dropped their price target on shares of Neurogene from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Neurogene has an average rating of “Moderate Buy” and an average target price of $46.17.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.